UK - Abingworth et al. invest £15m into Chroma Therapeutics

Oxford-based Chroma is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. The company was founded by Tony Kouzarides, research professor at the University of Cambridge, and Paul Workman, a director at the Institute of Cancer Research in Sutton. Chroma is building a pipeline of products based on the founders' expertise in chromatin biology and the company's novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages, a type of white blood cell that plays a key role in the immune system.

GlaxoSmithKline has recently signed an agreement with Chroma to collaborate together on the company's ESM technology, which enhances the delivery of drugs to specific targets within the cells. The pharmaceuticals giant has also contributed a signficant sum to this latest financing.

The new funding will be used to develop the company's aminopeptidase inhibitor, tosedostat, into late stage clinical studies in cancer, as well as to progress its macrophage-targeted HDAC inhibitor programme for cancer, CHR-2845, towards clinical proof of concept.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare